Pipeline Database
UB499
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB499
IndicationsMalignant neoplasm
ClinicalCN - I
TherapeuticsOncology
ModalitiesCGT
Exclusive Summary
- Innovative Mechanism: Recombinant L-IFN oncolytic adenovirus utilizes the 'Cancer Targeted Gene-Virotherapy (CTGVT)' strategy with dual regulation, offering broad-spectrum anti-cancer activity.
- Dual Regulatory Milestone: Successfully secured IND approvals from both the US FDA and China CDE, validating that its CMC and preclinical data meet stringent global regulatory standards.
- Strategic Asset: As a high-safety oncolytic virus with independent IP, it serves as an ideal candidate for combination therapies (e.g., with checkpoint inhibitors) to address cold tumors.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →